Drug Search Results
More Filters [+]

AG-024322

Alternative Names: ag-024322, ag024322, ag 024322
Latest Update: 2008-08-18
Latest Update Note: Clinical Trial Update

Product Description

AG-024322 may work in cancer by stopping cancer cells from multiplying. AG-024322 is and intravenous drug from a new class of drugs call cyclin-dependent kinase (CDK inhibitors). (Sourced from: https://www.clinicaltrials.gov/ct2/show/NCT00147485)

Mechanisms of Action: CDK Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for AG-024322

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Lymphoma, Non-Hodgkin

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

A7091001

P1

Terminated

Lymphoma, Non-Hodgkin

2007-08-01

Recent News Events

Date

Type

Title